2020
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabConceptsProgression-free survivalRandomized phase II trialPhase II trialOverall survivalHER2/neuStage IIICarboplatin-paclitaxelII trialRecurrent diseaseControl armSurvival analysisRecurrent uterine serous carcinomaCarboplatin/paclitaxelUterine serous carcinomaOverall survival analysisEvaluable patientsEligible patientsPrimary endpointSecondary endpointsEndometrial cancerAggressive variantSerous carcinomaPrimary treatmentSurvival medianPatients
2019
Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma
Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. Journal Of Neuro-Oncology 2019, 144: 107-115. PMID: 31190317, DOI: 10.1007/s11060-019-03208-w.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaDiffusion-weighted imaging patternsMagnetic resonance imagingCentral nervous system lymphomaNervous system lymphomaSystem lymphomaPeripheral enhancementDWI patternsPCNSL casesImaging featuresPrognostic markerHuman immunodeficiency virus (HIV) infectionKaplan-Meier survival analysisDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaMedian overall survivalImmunodeficiency virus infectionPredictors of survivalSolid organ transplantationImmunoglobulin heavy chain gene rearrangementPeripheral contrast enhancementLog-rank testMajor risk factorHeavy chain gene rearrangement
2018
FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors
Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.Peer-Reviewed Original ResearchConceptsSex cord-stromal tumorsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsCell tumorsReticulin patternFOXL2 mutationStaining patternSertoli-Leydig cell tumorFOXL2 mutation statusAbundant pale cytoplasmSingle institutional cohortThird of casesWild-type tumorsFOXL2 mutation analysisNegative tumorsPositive tumorsTumor sizeReticulin stainingType tumorsPale cytoplasmNuclear atypiaMutation statusPositive casesTumors
2017
Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2015
Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry
Alomari AK, Glusac EJ, Choi J, Hui P, Seeley EH, Caprioli RM, Watsky KL, Urban J, Lazova R. Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry. Journal Of Cutaneous Pathology 2015, 42: 757-764. PMID: 25989266, DOI: 10.1111/cup.12523.Peer-Reviewed Original ResearchConceptsMalignant melanomaCongenital neviInduction of laborLeft upper armThick malignant melanomaChallenging clinical scenarioMultiple mitotic figuresPatient underwentIntravascular invasionSentinel lymphMetastatic lesionsPregnant womenSex chromosome analysisMetastatic melanomaPolymerase chain reactionReddish noduleHistologic examinationResidual melanomaTransplacental metastasisMultiplex polymerase chain reactionDermal proliferationClinical scenariosLesionsNewborn boyUpper arm
2013
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
Buza N, Hui P. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes And Cancer 2013, 52: 1178-1186. PMID: 24123408, DOI: 10.1002/gcc.22113.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overEndometrial NeoplasmsFemaleFollow-Up StudiesGene AmplificationHumansMiddle AgedReceptor, ErbB-2ConceptsEndometrial serous carcinomaHER2/neu gene amplificationNeu gene amplificationSerous carcinomaHER2 protein expressionGene amplificationHeterogeneous tumorsProtein expressionHER2 testing guidelinesHER2 protein overexpressionTumor tissue areaTumor tissue sectionsHER2 statusDifferent tumor samplesHER2 overexpressionHER2 amplificationBreast cancerImmunohistochemical scoreAggressive subclonesCarcinomaClinical testingImmunostaining patternTumor samplesTumor cellsTesting guidelines
2012
Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis
Cai G, Mahooti S, Lipata FM, Chhieng D, Hui P. Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis. Cancer Cytopathology 2012, 120: 313-318. PMID: 22367918, DOI: 10.1002/cncy.21188.Peer-Reviewed Original Research
2011
Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions
Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Use of high‐risk human papillomavirus testing in patients with low‐grade squamous intraepithelial lesions. Cancer Cytopathology 2011, 119: 228-234. PMID: 21732551, DOI: 10.1002/cncy.20172.Peer-Reviewed Original ResearchConceptsLow-grade squamous intraepithelial lesionsHR-HPV testingHPV testingCIN 2Colposcopy rateHR-HPVRelative light units/cutoffCervical intraepithelial neoplasia 2High-risk human papillomavirusHR-HPV statusRLU/COIntraepithelial neoplasia 2Hybrid Capture 2Squamous intraepithelial lesionsCIN 1 lesionsLarge teaching hospitalNegative predictive valueLSIL cytologyHPV statusIntraepithelial lesionsCapture 2Human papillomavirusTeaching hospitalCytologic diagnosisSevere lesions